Loading…
Lantheus Holdings, Inc. is projected to rise to $133.97 by 2027, a +33% move from its current price of $101.00. LNTH is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/31/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Aug 1 | $98.90 | $101.02 | $103.19 | +0.02% |
| Aug 2 | $98.05 | $101.04 | $104.12 | +0.04% |
| Aug 3 | $97.41 | $101.06 | $104.85 | +0.06% |
| Aug 4 | $96.88 | $101.08 | $105.46 | +0.08% |
| Aug 5 | $96.42 | $101.10 | $106.02 | +0.10% |
| Aug 6 | $96.00 | $101.12 | $106.52 | +0.12% |
| Aug 7 | $95.62 | $101.14 | $106.98 | +0.14% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $95.62 | $101.14 | $106.98 | +0.14% |
| Week 2 | $93.55 | $101.29 | $109.66 | +0.28% |
| Week 3 | $92.03 | $101.43 | $111.79 | +0.42% |
| Week 4 | $90.78 | $101.57 | $113.64 | +0.57% |
| Week 5 | $89.71 | $101.72 | $115.32 | +0.71% |
| Week 6 | $88.77 | $101.86 | $116.88 | +0.85% |
| Week 7 | $87.92 | $102.00 | $118.34 | +0.99% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in diagnosis and treatment of heart, cancer, and other diseases worldwide. Its portfolio includes DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labeled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.
It also provides Automated Bone Scan Index that calculates the disease burden of prostate cancer by detecting and classifying bone scan tracer uptakes as metastatic or benign lesions using an artificial neural network; RELISTOR for opioid-induced constipation; and aPROMISE, an artificial intelligence medical device software; PYLARIFY AI, a medical device software to perform quantitative assessment of PSMA PET/CT images in prostate cancer; and flurpiridaz used to assess blood flow to the heart. In addition, it develops PNT2002, a radiopharmaceutical therapy to treat mCRPC; PNT2003, an SSTR therapy to patients with SSTR-positive neuroendocrine tumors; MK-6240, a F 18-labeled PET imaging agent for Tau tangles in Alzheimer's disease; LNTH-2401, a novel radiodiagnostic targeting the gastrin-releasing peptide receptor; LNTH-2402; LNTH-2403; LNTH-2404; LNTH-250; LNTH-2515; and LNTH-1363S, a fibroblast activation protein, alpha, copper-64 labeled PET imaging agent. It has collaboration agreements with GE Healthcare; Curium Pharma; POINT; Regeneron; and Ratio Therapeutics LLC.
The company was founded in 1956 and is based in Bedford, Massachusetts.
LNTH is the stock LNTH, currently trading at $104.61 with a market capitalization of $6.81B and a market position ranked 1107. The current price sits within a forecasted path that shows bullish potential over the coming years, with the 2026 average at $104.61 and higher upside projected through 2050.
A major floor 27.6% below — a decisive break under it would weaken the trend.
Price is testing support right now (1.0% away) — a key level to hold.
The nearest ceiling, 9.8% above — a clean break opens room to run.
A major ceiling 13.8% above — clearing it would confirm fresh momentum.
Key LNTH support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of LNTH market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $103.30 | Sell | $102.49 | Sell |
| MA 10 | $104.48 | Sell | $103.64 | Sell |
| MA 20 | $104.82 | Sell | $104.31 | Sell |
| MA 50 | $103.39 | Sell | $101.52 | Sell |
| MA 100 | $93.07 | Buy | $94.34 | Buy |
| MA 200 | $78.32 | Buy | $85.95 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 44.50 | Neutral |
| Stoch RSI (14) | 12.89 | Buy |
| CCI (20) | -134.63 | Sell |
| Williams %R (14) | -87.55 | Info |
| MACD (12,26,9) | -0.79 | Sell |
| ROC (12) | -1.34 | Sell |
| Bollinger %B (20,2) | 0.10 | Neutral |
| Stochastic %K (14) | 12.45 | Buy |
| TRIX (15) | 0.06 | Buy |
| Awesome (5,34) | -2.21 | Sell |
| Ultimate (7,14,28) | 36.31 | Neutral |
| Momentum (10) | -4.11 | Sell |
| Aroon Osc (25) | -80.00 | Sell |
| Hull MA (9) | 101.38 | Sell |
| ADX (14) | 13.48 | Neutral |
| ATR (14) | 2.17 | Info |
In the near term, the 30-day technical picture shows bullish sentiment overall. The RSI(14) is 50, placing the stock around neutral momentum. The 50-day simple moving average sits at $102.40, while the 200-day simple moving average is $76.81, indicating an upward tilt.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $64.25 | $101.00 | $134.21 | 0% | Neutral | |
| $109.00 | $133.97 | $172.67 | +33% | Bullish | |
| $131.54 | $165.18 | $219.41 | +64% | Bullish | |
| $163.02 | $208.34 | $283.36 | +106% | Bullish | |
| $184.72 | $239.74 | $332.62 | +137% | Bullish | |
| $200.60 | $264.00 | $372.72 | +161% | Bullish | |
| $223.83 | $298.41 | $427.95 | +195% | Bullish | |
| $232.59 | $313.85 | $456.55 | +211% | Bullish | |
| $268.15 | $365.99 | $539.41 | +262% | Bullish | |
| $330.88 | $456.53 | $681.13 | +352% | Bullish | |
| $467.89 | $677.81 | $1,064.67 | +571% | Bullish | |
| $1,037.67 | $1,631.15 | $2,763.97 | +15.2x | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $64.25 | $101.00 | $117.73 | +0.00% |
| August 2026 | $88.62 | $103.52 | $123.38 | +2.50% |
| September 2026 | $87.50 | $102.88 | $123.91 | -0.62% |
| October 2026 | $86.96 | $102.77 | $124.81 | -0.11% |
| November 2026 | $89.74 | $106.51 | $130.23 | +3.64% |
| December 2026 | $91.57 | $109.10 | $134.21 | +2.43% |
Click any year to see its month-by-month LNTH forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
In 2026, LNTH is projected to trade between $64.25 and $134.21, averaging $101.00 — a potential gain of 0% from today's $101.00. A consolidation phase looks the most probable path here.
Lantheus Holdings, Inc.'s 2027 outlook centres on $133.97, within a $109.00 to $172.67 range. That is up +33% on the projected 2026 average. That marks a +33% change versus current levels. Momentum favours further upside here.
By 2028, LNTH could reach as high as $219.41, with a base case around $165.18 and support toward $131.54 — roughly +64% from $101.00. Buyers look set to stay in control over this stretch.
Expect LNTH to range from $163.02 to $283.36 through 2029. The $208.34 average target implies a +106% move from current prices. That is up +26% on the projected 2028 average. Momentum favours further upside here.
The LNTH price prediction for 2030 points to an average of $239.74 (low $184.72, high $332.62) — a potential gain of +137% on today's $101.00. Buyers look set to stay in control over this stretch.
In 2031, LNTH is projected to trade between $200.60 and $372.72, averaging $264.00 — a potential gain of +161% from today's $101.00. That is up +10% on the projected 2030 average. Momentum favours further upside here.
Lantheus Holdings, Inc.'s 2032 outlook centres on $298.41, within a $223.83 to $427.95 range. That is up +13% on the projected 2031 average. That marks a +195% change versus current levels. Buyers look set to stay in control over this stretch.
By 2033, LNTH could reach as high as $456.55, with a base case around $313.85 and support toward $232.59 — roughly +211% from $101.00. Momentum favours further upside here.
Expect LNTH to range from $268.15 to $539.41 through 2034. The $365.99 average target implies a +262% move from current prices. That is up +17% on the projected 2033 average. Buyers look set to stay in control over this stretch.
The LNTH price prediction for 2035 points to an average of $456.53 (low $330.88, high $681.13) — a potential gain of +352% on today's $101.00. Momentum favours further upside here.
In 2040, LNTH is projected to trade between $467.89 and $1,064.67, averaging $677.81 — a potential gain of +571% from today's $101.00. That is up +48% on the projected 2035 average. Buyers look set to stay in control over this stretch.
Lantheus Holdings, Inc.'s 2050 outlook centres on $1,631.15, within a $1,037.67 to $2,763.97 range. That is up +141% on the projected 2040 average. That marks a +15.2x change versus current levels. Momentum favours further upside here.
Investing $1,000 in LNTH today (≈ 9.90099 LNTH) could be worth
$16,149.99
+$15,149.99 (+1515%) by 2050 · US Dollar
Based on the average projected LNTH price of $1,631.15 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in LNTHwould be worth at today's price.
$1,000 invested in LNTH on Jul 30, 2025 (≈ 13.919823 LNTH) would be worth
$1,405.9
+$405.9 (+40.6%) today · 1.41× · US Dollar
Based on a LNTH entry price of $71.84 vs. today's $101.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $103.73 | $973.68 | -2.6% |
| 1 month ago | $110.94 | $910.4 | -9.0% |
| 3 months ago | $85.5 | $1,181.29 | +18.1% |
| 6 months ago | $66.92 | $1,509.26 | +50.9% |
| 1 year ago | $71.84 | $1,405.9 | +40.6% |
| All time (5.0y) ago | $26.8 | $3,768.66 | +276.9% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our LNTH forecast.
Our base-case forecast reaches $200.00 around 2029.
Implied market cap at $200.00: $13.02B
Looking further out, the multi-year forecast presents a rising trajectory with substantial upside by 2030 and beyond. The 2030 average price is $244.08 with a corresponding ROI of 133.3% and bullish sentiment. By 2040 the average is $674.00, with a 544.3% ROI, continuing the bullish outlook.
The 2050 average reaches $1,594.78, accompanied by a 1424.5% ROI, underscoring a strong long-term upside with continued bullish momentum. These projections illustrate potential gains across successive decades, though they are estimates and not guarantees, subject to market and operating risks.
Tap a question to reveal the answer.
2030 average $244.08 with a min of $189.04 and a max of $336.41, corresponding to an estimated ROI of 133.3% and a bullish sentiment.
The forecast shows bullish sentiment from 2027 onward with rising average prices (e.g., $137.85 in 2027, $244.08 in 2030) and growing ROIs (up to 133.3% by 2030 and 1424.5% by 2050), indicating substantial upside potential while acknowledging the estimates are not guarantees.
Yes, the 2050 forecast average is $1,594.78, with a maximum of $2,666.45, suggesting that reaching well over $1,000 by 2050 is within the projected range.
The 30-day range is $91.50 to $119.60, with a current price of $104.61. RSI(14) is 50, SMA50 is $102.40, SMA200 is $76.81, with support at $99.98 and resistance at $110.94, and annualized volatility around 40%.
LNTH holds a market capitalization of $6.81B and is ranked 1107.
Lantheus Holdings, Inc. Community Discussion
0Share your Lantheus Holdings, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.